A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine in Adults Aged 18-59 Years
Latest Information Update: 01 Sep 2025
At a glance
- Drugs Influenza vaccine live attenuated (Nasovac-S) (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors Changchun BCHT Biotechnology
Most Recent Events
- 28 Aug 2025 New trial record